Identification

Name
Verapamil
Accession Number
DB00661  (APRD00335)
Type
Small Molecule
Groups
Approved
Description

A calcium channel blocker that is a class IV anti-arrhythmia agent.

Structure
Thumb
Synonyms
  • Iproveratril
  • Vérapamil
  • Verapamil
  • Verapamilo
  • Verapamilum
External IDs
CP-16,533-1 / D-365
Product Ingredients
IngredientUNIICASInChI Key
Verapamil hydrochlorideV3888OEY5R152-11-4DOQPXTMNIUCOSY-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CalanTablet, film coated80 mg/1OralG.D. Searle LLC Division of Pfizer Inc1984-09-10Not applicableUs
CalanTablet, film coated120 mg/1OralG.D. Searle LLC Division of Pfizer Inc1984-09-10Not applicableUs
Calan SRTablet, film coated, extended release120 mg/1OralG.D. Searle LLC Division of Pfizer Inc1991-03-06Not applicableUs
Calan SRTablet, film coated, extended release240 mg/1OralG.D. Searle LLC Division of Pfizer Inc1986-12-16Not applicableUs00025 1891 51 nlmimage10 4d132699
Calan SRTablet, film coated, extended release180 mg/1OralG.D. Searle LLC Division of Pfizer Inc1989-12-15Not applicableUs
Covera-HSTablet, extended release180 mg/1OralG.D. Searle LLC Division of Pfizer Inc1996-02-262016-10-13Us
Covera-HSTablet, extended release240 mgOralPfizer1997-11-132013-02-15Canada
Covera-HSTablet, extended release240 mg/1OralG.D. Searle LLC Division of Pfizer Inc1996-02-262016-10-13Us
Covera-HSTablet, extended release180 mgOralPfizer1997-11-132013-02-15Canada
Isoptin Inj 2.5mg/mlLiquid2.5 mgIntravenousAbbott1984-12-312007-07-31Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-verapamil - 120mgTablet120 mgOralAltimed Pharma Inc.1990-12-312004-08-03Canada
Alti-verapamil - 80mgTablet80 mgOralAltimed Pharma Inc.1990-12-312004-08-03Canada
Apo-verap SRTablet, extended release180 mgOralApotex Corporation2003-04-24Not applicableCanada
Apo-verap SRTablet, extended release120 mgOralApotex Corporation2003-04-24Not applicableCanada
Apo-verap SRTablet, extended release240 mgOralApotex Corporation2003-04-24Not applicableCanada
Apo-verap Tab 80mgTablet80 mgOralApotex Corporation1989-12-31Not applicableCanada
Apo-verap Tablet 120mgTablet120 mgOralApotex Corporation1989-12-31Not applicableCanada
Dom-verapamil SR 240mg TabletsTablet, extended release240 mgOralDominion Pharmacal1999-12-16Not applicableCanada
Mylan-verapamilTablet80 mgOralMylan Pharmaceuticals1998-05-25Not applicableCanada
Mylan-verapamilTablet120 mgOralMylan Pharmaceuticals1998-05-11Not applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
TarkaVerapamil hydrochloride (180 mg) + Trandolapril (2 mg)Tablet, extended releaseOralAbbott2002-07-152010-11-12Canada
TarkaVerapamil hydrochloride (240 mg/1) + Trandolapril (2 mg/1)Tablet, film coated, extended releaseOralPhysicians Total Care, Inc.2005-05-27Not applicableUs
TarkaVerapamil hydrochloride (240 mg/1) + Trandolapril (4 mg/1)Tablet, film coated, extended releaseOralAbbvie1996-10-22Not applicableUs
TarkaVerapamil hydrochloride (180 mg/1) + Trandolapril (2 mg/1)Tablet, film coated, extended releaseOralPhysicians Total Care, Inc.2009-01-01Not applicableUs
TarkaVerapamil hydrochloride (240 mg) + Trandolapril (2 mg)Tablet, extended releaseOralBgp Pharma Ulc2002-07-15Not applicableCanada
TarkaVerapamil hydrochloride (180 mg/1) + Trandolapril (2 mg/1)Tablet, film coated, extended releaseOralAbbvie1996-10-22Not applicableUs
TarkaVerapamil hydrochloride (240 mg) + Trandolapril (4 mg)Tablet, extended releaseOralBgp Pharma Ulc2002-07-15Not applicableCanada
TarkaVerapamil hydrochloride (240 mg/1) + Trandolapril (2 mg/1)Tablet, film coated, extended releaseOralAbbvie1996-10-22Not applicableUs
TarkaVerapamil hydrochloride (240 mg) + Trandolapril (1 mg)Tablet, extended releaseOralAbbott2002-07-152010-11-12Canada
TarkaVerapamil hydrochloride (240 mg/1) + Trandolapril (4 mg/1)Tablet, film coated, extended releaseOralPhysicians Total Care, Inc.2009-06-25Not applicableUs00074 3290 13 nlmimage10 ec1d766b
International/Other Brands
Bosoptin (Bosnalijek) / Isoptin (Abbott) / Verisop (Gerard) / Vermin (Ratiopharm) / Vermine (Pharmasant) / Verogalid (Ivax) / Verogalid ER (Ivax) / Verpamil (Mylan) / Vertab (Trinity-Chiesi) / Vetrimil (CCPC) / Zolvera (Rosemont)
Categories
UNII
CJ0O37KU29
CAS number
52-53-9
Weight
Average: 454.6016
Monoisotopic: 454.283157714
Chemical Formula
C27H38N2O4
InChI Key
SGTNSNPWRIOYBX-UHFFFAOYSA-N
InChI
InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3
IUPAC Name
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile
SMILES
COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1

Pharmacology

Indication

For the treatment of hypertension, angina, and cluster headache prophylaxis.

Associated Conditions
Pharmacodynamics

Verapamil is an L-type calcium channel blocker that also has antiarrythmic activity. The R-enantiomer is more effective at reducing blood pressure compared to the S-enantiomer. However, the S-enantiomer is 20 times more potent than the R-enantiomer at prolonging the PR interval in treating arrhythmias.

Mechanism of action

Verapamil inhibits voltage-dependent calcium channels. Specifically, its effect on L-type calcium channels in the heart causes a reduction in ionotropy and chronotropy, thuis reducing heart rate and blood pressure. Verapamil's mechanism of effect in cluster headache is thought to be linked to its calcium-channel blocker effect, but which channel subtypes are involved is presently not known.

TargetActionsOrganism
AVoltage-dependent L-type calcium channel subunit alpha-1C
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1D
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1F
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1S
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit beta-1
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit beta-2
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit beta-3
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit beta-4
inhibitor
Human
UVoltage-dependent T-type calcium channel subunit alpha-1I
inhibitor
Human
UVoltage-dependent T-type calcium channel subunit alpha-1G
inhibitor
Human
UVoltage-dependent N-type calcium channel subunit alpha-1B
inhibitor
Human
UVoltage-dependent P/Q-type calcium channel subunit alpha-1A
inhibitor
Human
UPotassium voltage-gated channel subfamily H member 2
inhibitor
Human
USodium channel protein type 5 subunit alpha
other
Human
UATP-sensitive inward rectifier potassium channel 11
inhibitor
Human
USodium-dependent serotonin transporter
other/unknown
Human
UAlpha-1A adrenergic receptor
antagonist
Human
UAlpha-1B adrenergic receptor
antagonist
Human
UAlpha-1D adrenergic receptor
antagonist
Human
Absorption

90%

Volume of distribution
Not Available
Protein binding

90%

Metabolism
Route of elimination

Approximately 70% of an administered dose is excreted as metabolites in the urine and 16% or more in the feces within 5 days. About 3% to 4% is excreted in the urine as unchanged drug.

Half life

2.8-7.4 hours

Clearance
Not Available
Toxicity

LD50=8 mg/kg (i.v. in mice)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Verapamil Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Beta-1 adrenergic receptor---(G;G) / (C;G)G > CEffect Directly StudiedPatients with this genotype require a lower dosage of verapamil to achieve a favourable rate-control response when treating atrial fibrillation.Details

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINEThe metabolism of Verapamil can be decreased when combined with (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE.Experimental
1,10-PhenanthrolineThe metabolism of Verapamil can be decreased when combined with 1,10-Phenanthroline.Experimental
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Verapamil.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Verapamil.Vet Approved
3,4-DichloroisocoumarinThe metabolism of Verapamil can be decreased when combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe metabolism of Verapamil can be decreased when combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
4-MethoxyamphetamineVerapamil may decrease the vasoconstricting activities of 4-Methoxyamphetamine.Experimental, Illicit
AbemaciclibThe metabolism of Abemaciclib can be decreased when combined with Verapamil.Approved, Investigational
AbirateroneThe serum concentration of Verapamil can be increased when it is combined with Abiraterone.Approved
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Verapamil.Approved, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Verapamil.Approved, Investigational
AcepromazineAcepromazine may increase the antihypertensive activities of Verapamil.Approved, Vet Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Verapamil.Approved
Acetyl sulfisoxazoleThe metabolism of Verapamil can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcetyldigitoxinVerapamil may increase the atrioventricular blocking (AV block) activities of Acetyldigitoxin.Approved
AcetyldigoxinVerapamil may increase the atrioventricular blocking (AV block) activities of Acetyldigoxin.Experimental
Acetylsalicylic acidVerapamil may increase the anticoagulant activities of Acetylsalicylic acid.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Verapamil.Approved
AdrafinilVerapamil may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Verapamil.Approved
AgmatineVerapamil may decrease the vasoconstricting activities of Agmatine.Experimental, Investigational
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Verapamil.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Verapamil.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Verapamil.Approved
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Verapamil.Approved, Illicit
AlfuzosinAlfuzosin may increase the antihypertensive activities of Verapamil.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be increased when it is combined with Verapamil.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Verapamil.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Verapamil.Approved, Investigational
AlogliptinThe metabolism of Verapamil can be decreased when combined with Alogliptin.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Verapamil.Approved, Withdrawn
AloxiprinVerapamil may increase the anticoagulant activities of Aloxiprin.Experimental
Alpha-1-proteinase inhibitorThe metabolism of Verapamil can be decreased when combined with Alpha-1-proteinase inhibitor.Approved
alpha-Tocopherol acetateThe metabolism of alpha-Tocopherol acetate can be decreased when combined with Verapamil.Approved
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Verapamil.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Verapamil.Approved, Withdrawn
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Verapamil.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Verapamil.Approved, Investigational
AmibegronVerapamil may decrease the vasoconstricting activities of Amibegron.Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Verapamil.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Verapamil.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Verapamil.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Verapamil.Approved
Aminosalicylic AcidVerapamil may increase the anticoagulant activities of Aminosalicylic Acid.Approved
AmiodaroneThe risk or severity of bradycardia can be increased when Verapamil is combined with Amiodarone.Approved, Investigational
AmitrazVerapamil may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineAmitriptyline may increase the antihypertensive activities of Verapamil.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Verapamil.Approved
AmobarbitalThe metabolism of Verapamil can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Verapamil.Approved, Investigational
AmoxapineAmoxapine may increase the antihypertensive activities of Verapamil.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Verapamil.Approved, Investigational
AmprenavirThe metabolism of Verapamil can be decreased when combined with Amprenavir.Approved, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Verapamil is combined with Amrinone.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Verapamil is combined with Amyl Nitrite.Approved
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Verapamil.Approved, Investigational
AnisodamineVerapamil may decrease the vasoconstricting activities of Anisodamine.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Verapamil.Approved, Investigational
Antithrombin III humanThe metabolism of Verapamil can be decreased when combined with Antithrombin III human.Approved
ApalutamideThe serum concentration of Verapamil can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Verapamil.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Verapamil.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Verapamil is combined with Apraclonidine.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Verapamil.Approved, Investigational
AprepitantThe serum concentration of Verapamil can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe metabolism of Verapamil can be decreased when combined with Aprotinin.Approved, Investigational, Withdrawn
AranidipineThe risk or severity of hypotension can be increased when Verapamil is combined with Aranidipine.Approved, Investigational
ArbutamineVerapamil may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolVerapamil may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
ArgatrobanThe metabolism of Verapamil can be decreased when combined with Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Verapamil.Approved, Investigational
ArmodafinilThe metabolism of Verapamil can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Verapamil.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Verapamil.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Verapamil.Approved
AsenapineAsenapine may increase the antihypertensive activities of Verapamil.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Verapamil.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Verapamil.Approved, Investigational, Withdrawn
AtazanavirThe metabolism of Verapamil can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the orthostatic hypotensive activities of Verapamil.Approved
AtomoxetineThe metabolism of Verapamil can be decreased when combined with Atomoxetine.Approved
AtorvastatinAtorvastatin can cause a decrease in the absorption of Verapamil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Verapamil.Approved
AvatrombopagThe metabolism of Avatrombopag can be decreased when combined with Verapamil.Approved, Investigational
AxitinibThe metabolism of Axitinib can be decreased when combined with Verapamil.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Verapamil.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Verapamil is combined with Azelnidipine.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Verapamil is combined with Azilsartan medoxomil.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Verapamil is combined with Azimilide.Investigational
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Verapamil.Approved
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Verapamil.Experimental
BalsalazideVerapamil may increase the anticoagulant activities of Balsalazide.Approved, Investigational
BambuterolVerapamil may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Verapamil.Investigational
BarbexacloneThe metabolism of Verapamil can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Verapamil can be increased when combined with Barbital.Illicit
BaricitinibThe metabolism of Baricitinib can be decreased when combined with Verapamil.Approved, Investigational
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Verapamil.Approved
BatimastatThe metabolism of Verapamil can be decreased when combined with Batimastat.Experimental
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Verapamil.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Verapamil.Experimental
BenazeprilThe metabolism of Verapamil can be decreased when combined with Benazepril.Approved, Investigational
BencyclaneThe risk or severity of hypotension can be increased when Verapamil is combined with Bencyclane.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Verapamil.Approved
BenidipineThe metabolism of Benidipine can be decreased when combined with Verapamil.Approved, Investigational
BenzamidineThe metabolism of Verapamil can be decreased when combined with Benzamidine.Experimental
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Verapamil.Approved, Investigational
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Verapamil.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Verapamil.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Verapamil.Approved, Withdrawn
BeractantVerapamil may increase the bradycardic activities of Beractant.Approved
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Verapamil.Approved, Investigational
BevantololBevantolol may increase the antihypertensive activities of Verapamil.Approved
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Verapamil.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Verapamil.Approved, Investigational
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Verapamil.Approved
BictegravirThe metabolism of Bictegravir can be decreased when combined with Verapamil.Approved, Investigational
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Verapamil.Approved, Investigational
BioallethrinThe metabolism of Bioallethrin can be decreased when combined with Verapamil.Approved, Experimental
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Verapamil.Approved
BitolterolVerapamil may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BivalirudinThe metabolism of Verapamil can be decreased when combined with Bivalirudin.Approved, Investigational
BlonanserinThe metabolism of Blonanserin can be decreased when combined with Verapamil.Approved, Investigational
BoceprevirThe metabolism of Verapamil can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Verapamil.Approved
BortezomibThe metabolism of Verapamil can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Verapamil.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Verapamil.Approved
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Verapamil.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Verapamil.Approved, Investigational
BretyliumBretylium may increase the bradycardic activities of Verapamil.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Verapamil.Approved, Investigational
BrigatinibThe metabolism of Brigatinib can be decreased when combined with Verapamil.Approved, Investigational
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Verapamil.Approved
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Verapamil.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Verapamil.Approved, Investigational
BromazepamThe metabolism of Bromazepam can be decreased when combined with Verapamil.Approved, Illicit, Investigational
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Verapamil.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Verapamil.Approved
BucindololBucindolol may increase the antihypertensive activities of Verapamil.Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Verapamil.Approved
BufuralolBufuralol may increase the orthostatic hypotensive activities of Verapamil.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Verapamil is combined with Bumetanide.Approved
BunazosinBunazosin may increase the antihypertensive activities of Verapamil.Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Verapamil.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Verapamil.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Verapamil.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Verapamil.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Verapamil.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Verapamil.Approved, Investigational
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Verapamil.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Verapamil.Approved
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Verapamil.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Verapamil.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Verapamil.Approved, Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Verapamil.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Verapamil.Approved, Nutraceutical
Calcium AcetateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Phosphate.Approved
CalfactantVerapamil may increase the bradycardic activities of Calfactant.Approved
CamostatThe metabolism of Verapamil can be decreased when combined with Camostat.Experimental
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Verapamil.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Verapamil is combined with Candesartan cilexetil.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Verapamil.Withdrawn
CandoxatrilThe metabolism of Verapamil can be decreased when combined with Candoxatril.Experimental
CandoxatrilatThe metabolism of Verapamil can be decreased when combined with Candoxatrilat.Experimental
CannabidiolThe metabolism of Cannabidiol can be decreased when combined with Verapamil.Approved, Investigational
CapecitabineThe metabolism of Verapamil can be decreased when combined with Capecitabine.Approved, Investigational
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Verapamil.Experimental
CaptoprilThe metabolism of Verapamil can be decreased when combined with Captopril.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Verapamil.Approved, Investigational
Carbaspirin calciumVerapamil may increase the anticoagulant activities of Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Verapamil.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Verapamil.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Verapamil is combined with Carboxyamidotriazole.Investigational
CariprazineThe metabolism of Cariprazine can be decreased when combined with Verapamil.Approved, Investigational
CaroverineThe risk or severity of hypotension can be increased when Verapamil is combined with Caroverine.Experimental
CarteololCarteolol may increase the orthostatic hypotensive activities of Verapamil.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Verapamil.Approved, Investigational
CaseinThe therapeutic efficacy of Verapamil can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Verapamil.Approved
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Verapamil.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Verapamil.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
CeritinibVerapamil may increase the bradycardic activities of Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Verapamil.Approved, Withdrawn
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Verapamil.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Verapamil.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Verapamil.Approved
ChloramphenicolThe metabolism of Verapamil can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Verapamil.Approved, Illicit, Investigational
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Verapamil is combined with Chlorothiazide.Approved, Vet Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Verapamil.Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Verapamil.Approved
ChlorpromazineChlorpromazine may increase the antihypertensive activities of Verapamil.Approved, Investigational, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Verapamil.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Verapamil.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Verapamil.Approved, Nutraceutical
Cholic AcidVerapamil may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
ChymostatinThe metabolism of Verapamil can be decreased when combined with Chymostatin.Experimental
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Verapamil.Approved, Investigational
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Verapamil.Approved, Investigational
CilastatinThe metabolism of Verapamil can be decreased when combined with Cilastatin.Approved, Investigational
CilazaprilThe metabolism of Verapamil can be decreased when combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Verapamil.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Verapamil.Approved, Investigational
CimetidineThe serum concentration of Verapamil can be increased when it is combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Verapamil.Approved
CinnarizineThe risk or severity of hypotension can be increased when Verapamil is combined with Cinnarizine.Approved, Investigational
CirazolineVerapamil may decrease the vasoconstricting activities of Cirazoline.Experimental
CisaprideThe metabolism of Cisapride can be decreased when combined with Verapamil.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Citalopram can be decreased when combined with Verapamil.Approved
ClarithromycinThe metabolism of Verapamil can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Verapamil can be decreased when combined with Clemastine.Approved, Investigational
ClenbuterolVerapamil may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineClevidipine may increase the hypotensive activities of Verapamil.Approved, Investigational
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Verapamil.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Verapamil.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Verapamil.Approved, Investigational
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Verapamil.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Verapamil.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Verapamil.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Verapamil.Approved, Illicit
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Verapamil.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Verapamil.Approved
CloranololCloranolol may increase the orthostatic hypotensive activities of Verapamil.Experimental
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Verapamil.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Verapamil.Approved, Illicit
ClotrimazoleThe metabolism of Verapamil can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the antihypertensive activities of Verapamil.Approved
CobicistatThe metabolism of Verapamil can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Verapamil.Approved, Investigational
CocaineThe metabolism of Cocaine can be decreased when combined with Verapamil.Approved, Illicit
CodeineThe metabolism of Codeine can be decreased when combined with Verapamil.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Verapamil.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Verapamil.Approved, Investigational
Conjugated estrogensThe metabolism of Conjugated estrogens can be decreased when combined with Verapamil.Approved
CopanlisibThe metabolism of Copanlisib can be decreased when combined with Verapamil.Approved, Investigational
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Verapamil.Investigational
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Verapamil.Approved, Investigational
CrisaboroleThe metabolism of Verapamil can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe metabolism of Crizotinib can be decreased when combined with Verapamil.Approved
CurcuminThe metabolism of Verapamil can be decreased when combined with Curcumin.Approved, Investigational
CyclandelateThe risk or severity of hypotension can be increased when Verapamil is combined with Cyclandelate.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Verapamil.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Verapamil.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
CymarinVerapamil may increase the atrioventricular blocking (AV block) activities of Cymarin.Experimental
Cyproterone acetateThe serum concentration of Verapamil can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe metabolism of Cytarabine can be decreased when combined with Verapamil.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Verapamil.Approved
DabrafenibThe serum concentration of Verapamil can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Verapamil.Approved, Investigational
DantroleneDantrolene may increase the hyperkalemic activities of Verapamil.Approved, Investigational
DantroleneThe metabolism of Dantrolene can be decreased when combined with Verapamil.Approved, Investigational
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Verapamil.Approved
DapiprazoleDapiprazole may increase the antihypertensive activities of Verapamil.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Verapamil.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Verapamil.Approved, Investigational
DarexabanThe metabolism of Verapamil can be decreased when combined with Darexaban.Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Verapamil.Approved, Investigational
DarodipineThe risk or severity of hypotension can be increased when Verapamil is combined with Darodipine.Experimental
DarunavirThe metabolism of Verapamil can be decreased when combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Verapamil.Approved
DasatinibThe serum concentration of Verapamil can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Verapamil.Approved
DeferasiroxThe serum concentration of Verapamil can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe metabolism of Deflazacort can be decreased when combined with Verapamil.Approved, Investigational
DelamanidThe metabolism of Delamanid can be decreased when combined with Verapamil.Approved, Investigational
DelanzomibThe metabolism of Verapamil can be decreased when combined with Delanzomib.Investigational
DelaprilThe metabolism of Verapamil can be decreased when combined with Delapril.Investigational
DelavirdineThe metabolism of Verapamil can be decreased when combined with Delavirdine.Approved
DersalazineVerapamil may increase the anticoagulant activities of Dersalazine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Verapamil.Approved
DesipramineDesipramine may increase the orthostatic hypotensive activities of Verapamil.Approved, Investigational
DeslanosideVerapamil may increase the atrioventricular blocking (AV block) activities of Deslanoside.Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Verapamil.Approved, Investigational
DetomidineVerapamil may decrease the vasoconstricting activities of Detomidine.Vet Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Verapamil.Approved, Investigational
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Verapamil.Approved
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Verapamil.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Verapamil.Approved, Vet Approved
DextroamphetamineVerapamil may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Verapamil.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Verapamil.Approved, Illicit, Investigational, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Verapamil.Approved, Illicit, Investigational, Vet Approved
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Verapamil.Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Verapamil.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Verapamil is combined with Diclofenamide.Approved, Investigational
DienogestThe metabolism of Dienogest can be decreased when combined with Verapamil.Approved
DiflunisalVerapamil may increase the anticoagulant activities of Diflunisal.Approved, Investigational
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Verapamil.Approved, Investigational
DigoxinThe metabolism of Digoxin can be decreased when combined with Verapamil.Approved
Digoxin Immune Fab (Ovine)Verapamil may increase the atrioventricular blocking (AV block) activities of Digoxin Immune Fab (Ovine).Approved
Dihydro-alpha-ergocryptineThe metabolism of Dihydro-alpha-ergocryptine can be decreased when combined with Verapamil.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Verapamil.Approved, Illicit
DihydroergotamineThe metabolism of Verapamil can be decreased when combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe metabolism of Verapamil can be decreased when combined with Diltiazem.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Verapamil is combined with Dinutuximab.Approved, Investigational
DipivefrinVerapamil may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Verapamil.Approved
DisopyramideThe risk or severity of sinus node depression can be increased when Verapamil is combined with Disopyramide.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Verapamil.Approved
DL-MethylephedrineVerapamil may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutamineVerapamil may decrease the vasoconstricting activities of Dobutamine.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Verapamil.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Verapamil.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Verapamil.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Verapamil.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Verapamil.Approved
DopexamineVerapamil may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Verapamil.Approved
DosulepinThe metabolism of Verapamil can be decreased when combined with Dosulepin.Approved
DotarizineThe risk or severity of hypotension can be increased when Verapamil is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Verapamil.Approved
DoxepinDoxepin may increase the antihypertensive activities of Verapamil.Approved, Investigational
DoxofyllineVerapamil may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Verapamil.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Verapamil.Approved, Investigational
DoxycyclineThe metabolism of Verapamil can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Verapamil.Approved, Illicit
DronedaroneVerapamil may increase the atrioventricular blocking (AV block) activities of Dronedarone.Approved
DroperidolDroperidol may increase the antihypertensive activities of Verapamil.Approved, Vet Approved
DroxidopaVerapamil may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DuloxetineVerapamil may increase the orthostatic hypotensive activities of Duloxetine.Approved
DutasterideThe metabolism of Dutasteride can be decreased when combined with Verapamil.Approved, Investigational
EcabetThe metabolism of Verapamil can be decreased when combined with Ecabet.Approved, Investigational
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Verapamil.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Verapamil.Approved
EfavirenzThe serum concentration of Verapamil can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Verapamil.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Verapamil.Approved, Investigational
ElafinThe metabolism of Verapamil can be decreased when combined with Elafin.Investigational
ElbasvirThe metabolism of Elbasvir can be decreased when combined with Verapamil.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Verapamil.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Verapamil.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Verapamil.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Verapamil is combined with Empagliflozin.Approved
EnalaprilThe metabolism of Verapamil can be decreased when combined with Enalapril.Approved, Vet Approved
EnalaprilatThe metabolism of Verapamil can be decreased when combined with Enalaprilat.Approved
EnalkirenThe metabolism of Verapamil can be decreased when combined with Enalkiren.Experimental
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Verapamil.Approved, Investigational
EnzalutamideThe serum concentration of Verapamil can be decreased when it is combined with Enzalutamide.Approved
EpanololEpanolol may increase the orthostatic hypotensive activities of Verapamil.Experimental
EperisoneThe risk or severity of hypotension can be increased when Verapamil is combined with Eperisone.Approved, Investigational
EphedraVerapamil may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineVerapamil may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Verapamil.Approved, Investigational
EpinephrineVerapamil may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Verapamil.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Verapamil.Approved
EprosartanThe risk or severity of adverse effects can be increased when Verapamil is combined with Eprosartan.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Verapamil.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Verapamil.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Verapamil.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Verapamil.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Verapamil.Approved, Investigational
ErythromycinThe metabolism of Verapamil can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Verapamil.Experimental
EscitalopramEscitalopram may increase the antihypertensive activities of Verapamil.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Verapamil can be decreased when combined with Eslicarbazepine acetate.Approved
EsmololEsmolol may increase the orthostatic hypotensive activities of Verapamil.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Verapamil.Approved, Investigational
EstazolamThe metabolism of Estazolam can be decreased when combined with Verapamil.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
Estradiol acetateThe metabolism of Estradiol acetate can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
Estradiol benzoateThe metabolism of Estradiol benzoate can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
Estradiol cypionateThe metabolism of Estradiol cypionate can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
Estradiol dienanthateThe metabolism of Estradiol dienanthate can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
Estradiol valerateThe metabolism of Estradiol valerate can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Verapamil.Approved, Investigational
Estrogens, esterifiedThe metabolism of Estrogens, esterified can be decreased when combined with Verapamil.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Verapamil.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Verapamil.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Verapamil.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Verapamil is combined with Etacrynic acid.Approved, Investigational
EtafedrineVerapamil may decrease the vasoconstricting activities of Etafedrine.Approved
EthanolThe serum concentration of Ethanol can be increased when it is combined with Verapamil.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Verapamil.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Verapamil.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Verapamil.Approved, Illicit
EtilefrineVerapamil may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtizolamThe metabolism of Etizolam can be decreased when combined with Verapamil.Approved
EtomidateVerapamil may decrease the vasoconstricting activities of Etomidate.Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Verapamil.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Verapamil.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Verapamil.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Verapamil.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Verapamil.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Verapamil.Approved, Investigational
FaldaprevirThe metabolism of Verapamil can be decreased when combined with Faldaprevir.Investigational
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Verapamil.Approved, Investigational
FelbamateThe metabolism of Felbamate can be decreased when combined with Verapamil.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Verapamil.Approved, Investigational
FendilineThe risk or severity of hypotension can be increased when Verapamil is combined with Fendiline.Withdrawn
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Verapamil.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Verapamil.Approved
FenoterolVerapamil may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Verapamil.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Verapamil.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Verapamil.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Verapamil.Approved, Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Verapamil.Approved, Investigational
FinasterideThe metabolism of Finasteride can be decreased when combined with Verapamil.Approved
FingolimodThe risk or severity of bradycardia can be increased when Verapamil is combined with Fingolimod.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Verapamil is combined with Fish oil.Approved, Nutraceutical
FlecainideThe risk or severity of adverse effects can be increased when Verapamil is combined with Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Verapamil is combined with Flibanserin.Approved, Investigational
FloxuridineThe metabolism of Verapamil can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Verapamil can be decreased when combined with Fluconazole.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Verapamil.Approved, Investigational
FlunarizineThe risk or severity of hypotension can be increased when Verapamil is combined with Flunarizine.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Verapamil.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Verapamil.Approved, Illicit
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Verapamil.Approved, Investigational
FluorouracilThe metabolism of Verapamil can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Verapamil.Approved, Vet Approved
FlupentixolFlupentixol may increase the antihypertensive activities of Verapamil.Approved, Investigational, Withdrawn
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Verapamil.Approved, Illicit, Investigational
FluspirileneThe risk or severity of hypotension can be increased when Verapamil is combined with Fluspirilene.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Verapamil.Approved, Investigational
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Verapamil.Approved
Fluticasone propionateThe metabolism of Fluticasone propionate can be decreased when combined with Verapamil.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Verapamil.Experimental
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Verapamil.Approved
FluvoxamineThe metabolism of Verapamil can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolVerapamil may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Verapamil can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Verapamil can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe metabolism of Verapamil can be decreased when combined with Fosinopril.Approved
FosnetupitantThe metabolism of Fosnetupitant can be decreased when combined with Verapamil.Approved
FosphenytoinThe metabolism of Verapamil can be increased when combined with Fosphenytoin.Approved, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Verapamil.Approved, Investigational
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Verapamil.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Verapamil is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Verapamil can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of hypotension can be increased when Verapamil is combined with Gabapentin.Approved, Investigational
GabexateThe metabolism of Verapamil can be decreased when combined with Gabexate.Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Verapamil.Approved
GallopamilThe risk or severity of hypotension can be increased when Verapamil is combined with Gallopamil.Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Verapamil.Approved, Investigational
GeldanamycinThe metabolism of Verapamil can be decreased when combined with Geldanamycin.Experimental, Investigational
GemfibrozilThe metabolism of Verapamil can be decreased when combined with Gemfibrozil.Approved
GitoformateVerapamil may increase the atrioventricular blocking (AV block) activities of Gitoformate.Experimental
GlipizideThe metabolism of Glipizide can be decreased when combined with Verapamil.Approved, Investigational
GlyburideThe metabolism of Glyburide can be decreased when combined with Verapamil.Approved
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Verapamil.Experimental
GM6001The metabolism of Verapamil can be decreased when combined with GM6001.Experimental
GranisetronThe metabolism of Granisetron can be decreased when combined with Verapamil.Approved, Investigational
GrazoprevirThe metabolism of Grazoprevir can be decreased when combined with Verapamil.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Verapamil.Approved, Investigational, Withdrawn
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Verapamil.Approved, Investigational, Vet Approved
GuacetisalVerapamil may increase the anticoagulant activities of Guacetisal.Experimental
GuanabenzVerapamil may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Verapamil.Approved, Investigational
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Verapamil.Experimental
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Verapamil.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Verapamil.Approved
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Verapamil.Approved, Withdrawn
HalothaneThe metabolism of Halothane can be decreased when combined with Verapamil.Approved, Vet Approved
Hemoglobin crosfumarilVerapamil may increase the anticoagulant activities of Hemoglobin crosfumaril.Experimental
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Verapamil.Approved, Investigational
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Verapamil.Approved
HexoprenalineVerapamil may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineVerapamil may decrease the vasoconstricting activities of Higenamine.Investigational
HistamineThe metabolism of Histamine can be decreased when combined with Verapamil.Approved, Investigational
HydralazineThe risk or severity of adverse effects can be increased when Verapamil is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Verapamil is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Verapamil.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Verapamil.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Verapamil.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Verapamil.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Verapamil.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Verapamil.Approved
IcotinibThe metabolism of Icotinib can be decreased when combined with Verapamil.Approved, Investigational
IdelalisibThe metabolism of Verapamil can be decreased when combined with Idelalisib.Approved
IdraparinuxThe metabolism of Verapamil can be decreased when combined with Idraparinux.Investigational
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Verapamil resulting in a loss in efficacy.Approved
IloperidoneIloperidone may increase the antihypertensive activities of Verapamil.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Verapamil.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Verapamil.Approved
ImidafenacinThe metabolism of Imidafenacin can be decreased when combined with Verapamil.Approved, Investigational
ImidaprilThe metabolism of Verapamil can be decreased when combined with Imidapril.Investigational
ImipramineImipramine may increase the antihypertensive activities of Verapamil.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Verapamil.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Verapamil.Approved
IndapamideThe metabolism of Indapamide can be decreased when combined with Verapamil.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Verapamil.Withdrawn
IndinavirThe metabolism of Verapamil can be decreased when combined with Indinavir.Approved
IndoraminIndoramin may increase the antihypertensive activities of Verapamil.Withdrawn
IpecacThe metabolism of Ipecac can be decreased when combined with Verapamil.Approved, Withdrawn
IpratropiumThe metabolism of Ipratropium bromide can be decreased when combined with Verapamil.Approved
IrbesartanThe metabolism of Verapamil can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Verapamil.Approved, Investigational
IsavuconazoleThe serum concentration of Verapamil can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Verapamil.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Verapamil.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Verapamil.Approved
IsoetarineVerapamil may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Verapamil.Approved, Vet Approved
IsoflurophateThe metabolism of Verapamil can be decreased when combined with Isoflurophate.Approved, Investigational, Withdrawn
IsomethepteneVerapamil may decrease the vasoconstricting activities of Isometheptene.Approved
IsoniazidThe metabolism of Verapamil can be decreased when combined with Isoniazid.Approved, Investigational
IsoprenalineVerapamil may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Verapamil.Approved, Investigational
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Verapamil.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Verapamil is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Verapamil can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Verapamil can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Verapamil.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Verapamil.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Verapamil.Approved, Investigational
IxazomibThe metabolism of Verapamil can be decreased when combined with Ixazomib.Approved, Investigational
KetamineThe metabolism of Ketamine can be decreased when combined with Verapamil.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Verapamil.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Verapamil.Approved, Investigational
KetoconazoleThe metabolism of Verapamil can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolLabetalol may increase the antihypertensive activities of Verapamil.Approved
LacidipineVerapamil may increase the hypotensive activities of Lacidipine.Approved, Investigational
LacosamideVerapamil may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LamotrigineThe risk or severity of hypotension can be increased when Verapamil is combined with Lamotrigine.Approved, Investigational
Lanatoside CVerapamil may increase the atrioventricular blocking (AV block) activities of Lanatoside C.Experimental
LandiololLandiolol may increase the orthostatic hypotensive activities of Verapamil.Investigational
LanreotideVerapamil may increase the bradycardic activities of Lanreotide.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Verapamil.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Verapamil.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Verapamil.Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Verapamil.Approved
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Verapamil.Approved
LeflunomideThe metabolism of Verapamil can be decreased when combined with Leflunomide.Approved, Investigational
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Verapamil.Approved, Investigational
LepirudinThe metabolism of Verapamil can be decreased when combined with Lepirudin.Approved
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Verapamil.Approved, Investigational
LetaxabanThe metabolism of Verapamil can be decreased when combined with Letaxaban.Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Verapamil.Approved, Investigational
LevetiracetamThe risk or severity of hypotension can be increased when Verapamil is combined with Levetiracetam.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Verapamil.Approved, Investigational
LevobunololVerapamil may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Verapamil.Approved, Investigational
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Verapamil.Approved
LevodopaVerapamil may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Verapamil.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Verapamil.Approved, Investigational
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Verapamil.Approved, Investigational
LevosalbutamolVerapamil may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Verapamil.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Verapamil.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Verapamil.Approved, Vet Approved
LidoflazineThe risk or severity of hypotension can be increased when Verapamil is combined with Lidoflazine.Experimental
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Verapamil.Approved
LisdexamfetamineVerapamil may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe metabolism of Verapamil can be decreased when combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Verapamil.Approved, Investigational
Lithium cationVerapamil may increase the neurotoxic activities of Lithium.Experimental
LobeglitazoneThe metabolism of Verapamil can be decreased when combined with Lobeglitazone.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Verapamil.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Verapamil.Approved, Investigational
LoperamideThe metabolism of Loperamide can be decreased when combined with Verapamil.Approved
LopinavirThe metabolism of Verapamil can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Verapamil.Approved, Investigational
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Verapamil.Approved
LorpiprazoleThe serum concentration of Verapamil can be increased when it is combined with Lorpiprazole.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Verapamil.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Verapamil.Approved, Investigational
LucinactantVerapamil may increase the bradycardic activities of Lucinactant.Approved, Investigational
LuliconazoleThe serum concentration of Verapamil can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Verapamil can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Lumefantrine can be decreased when combined with Verapamil.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Verapamil.Approved, Investigational
MacimorelinThe metabolism of Macimorelin can be decreased when combined with Verapamil.Approved, Investigational
MacitentanThe metabolism of Macitentan can be decreased when combined with Verapamil.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Verapamil is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Verapamil is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Verapamil is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Verapamil is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Verapamil can be decreased when combined with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Verapamil is combined with Mannitol.Approved, Investigational
MaravirocThe metabolism of Maraviroc can be decreased when combined with Verapamil.Approved, Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Verapamil.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Verapamil.Approved, Investigational
MedetomidineVerapamil may decrease the vasoconstricting activities of Medetomidine.Vet Approved
Medical CannabisThe metabolism of Medical Cannabis can be decreased when combined with Verapamil.Experimental, Investigational
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Verapamil.Approved, Investigational
MefloquineThe metabolism of Mefloquine can be decreased when combined with Verapamil.Approved, Investigational
MelagatranThe metabolism of Verapamil can be decreased when combined with Melagatran.Experimental
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Verapamil.Approved, Vet Approved
MentholThe risk or severity of hypotension can be increased when Verapamil is combined with Menthol.Approved
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Verapamil.Experimental
MephentermineVerapamil may decrease the vasoconstricting activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Verapamil.Experimental
MesalazineVerapamil may increase the anticoagulant activities of Mesalazine.Approved
MetaraminolVerapamil may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Verapamil.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Verapamil.Approved
MethamphetamineVerapamil may decrease the vasoconstricting activities of Methamphetamine.Approved, Illicit
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Verapamil.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Verapamil is combined with Methazolamide.Approved
MethohexitalThe metabolism of Verapamil can be increased when combined with Methohexital.Approved
MethotrimeprazineMethotrimeprazine may increase the antihypertensive activities of Verapamil.Approved, Investigational
MethoxamineVerapamil may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Verapamil.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
MethoxyphenamineVerapamil may decrease the vasoconstricting activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of hypotension can be increased when Verapamil is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Verapamil.Approved
Methyl salicylateVerapamil may increase the anticoagulant activities of Methyl salicylate.Approved, Vet Approved
MethyldopaThe risk or severity of adverse effects can be increased when Verapamil is combined with Methyldopa.Approved
MethylphenobarbitalThe metabolism of Verapamil can be increased when combined with Methylphenobarbital.Approved
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Verapamil.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Verapamil.Approved
MetildigoxinVerapamil may increase the atrioventricular blocking (AV block) activities of Metildigoxin.Experimental
MetipranololVerapamil may increase the hypotensive activities of Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Verapamil.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Verapamil.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Verapamil.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Verapamil.Experimental
MexiletineThe metabolism of Verapamil can be decreased when combined with Mexiletine.Approved, Investigational
MianserinThe metabolism of Mianserin can be decreased when combined with Verapamil.Approved, Investigational
MibefradilThe metabolism of Mibefradil can be decreased when combined with Verapamil.Investigational, Withdrawn
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Verapamil.Approved, Investigational
MiconazoleThe metabolism of Miconazole can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Verapamil.Approved, Illicit
MidecamycinThe metabolism of Midecamycin can be decreased when combined with Verapamil.Approved
MidodrineVerapamil may increase the bradycardic activities of Midodrine.Approved
MidostaurinThe metabolism of Verapamil can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Verapamil can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Verapamil.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Verapamil.Approved, Investigational
MirabegronThe metabolism of Mirabegron can be decreased when combined with Verapamil.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Verapamil.Investigational
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Verapamil.Approved
MitotaneThe serum concentration of Verapamil can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Verapamil can be decreased when combined with Moclobemide.Approved, Investigational
ModafinilThe metabolism of Modafinil can be decreased when combined with Verapamil.Approved, Investigational
MoexiprilThe metabolism of Verapamil can be decreased when combined with Moexipril.Approved
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Verapamil.Vet Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Verapamil.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Verapamil.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Verapamil.Approved, Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Verapamil.Approved, Investigational
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Verapamil.Experimental
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe metabolism of Verapamil can be decreased when combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Verapamil.Approved, Investigational
NabiximolsThe metabolism of Nabiximols can be decreased when combined with Verapamil.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Verapamil.Approved
NafamostatThe metabolism of Verapamil can be decreased when combined with Nafamostat.Approved, Investigational
NafcillinThe therapeutic efficacy of Verapamil can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Verapamil.Approved
NaftopidilThe risk or severity of hypotension can be increased when Verapamil is combined with Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Verapamil.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Verapamil.Approved, Vet Approved
NaphazolineVerapamil may decrease the vasoconstricting activities of Naphazoline.Approved
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Verapamil.Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Verapamil.Approved, Investigational
NebivololNebivolol may increase the orthostatic hypotensive activities of Verapamil.Approved, Investigational
NefazodoneNefazodone may increase the antihypertensive activities of Verapamil.Approved, Withdrawn
NelfinavirThe metabolism of Verapamil can be decreased when combined with Nelfinavir.Approved
NeratinibThe metabolism of Neratinib can be decreased when combined with Verapamil.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Verapamil is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Verapamil can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Verapamil can be increased when combined with Nevirapine.Approved
NicardipineNicardipine may increase the antihypertensive activities of Verapamil.Approved, Investigational
NicergolineNicergoline may increase the antihypertensive activities of Verapamil.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Verapamil.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Verapamil.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Verapamil.Approved
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Verapamil.Experimental
NiguldipineNiguldipine may increase the antihypertensive activities of Verapamil.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Verapamil.Investigational
NilotinibThe metabolism of Nilotinib can be decreased when combined with Verapamil.Approved, Investigational
NiludipineThe risk or severity of hypotension can be increased when Verapamil is combined with Niludipine.Experimental
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Verapamil.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Verapamil is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Verapamil.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Verapamil.Approved
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Verapamil.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Verapamil.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Verapamil.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Verapamil.Approved
NitroaspirinVerapamil may increase the anticoagulant activities of Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Verapamil is combined with Nitroglycerin.Approved, Investigational
NitroprussideVerapamil may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Verapamil.Approved, Investigational
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Verapamil.Approved
NorepinephrineVerapamil may decrease the vasoconstricting activities of Norepinephrine.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Verapamil.Approved
NorfenefrineVerapamil may decrease the vasoconstricting activities of Norfenefrine.Experimental
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Verapamil.Approved
NortriptylineNortriptyline may increase the antihypertensive activities of Verapamil.Approved
NylidrinVerapamil may decrease the vasoconstricting activities of Nylidrin.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Verapamil.Approved, Vet Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Verapamil.Approved, Investigational
OctopamineVerapamil may decrease the vasoconstricting activities of Octopamine.Experimental
OctreotideOctreotide may increase the bradycardic activities of Verapamil.Approved, Investigational
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Verapamil.Investigational
OlanzapineOlanzapine may increase the antihypertensive activities of Verapamil.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Verapamil.Approved
OleandrinVerapamil may increase the atrioventricular blocking (AV block) activities of Oleandrin.Experimental, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Verapamil.Approved, Investigational
OlodaterolVerapamil may decrease the vasoconstricting activities of Olodaterol.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Verapamil.Approved
OlsalazineVerapamil may increase the anticoagulant activities of Olsalazine.Approved
OmapatrilatThe metabolism of Verapamil can be decreased when combined with Omapatrilat.Investigational
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Verapamil.Experimental
OndansetronThe metabolism of Ondansetron can be decreased when combined with Verapamil.Approved
OpiumThe metabolism of Opium can be decreased when combined with Verapamil.Approved, Illicit
OrciprenalineVerapamil may decrease the vasoconstricting activities of Orciprenaline.Approved
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Verapamil.Approved
OsimertinibThe serum concentration of Verapamil can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Verapamil.Approved, Investigational
OtamixabanThe metabolism of Verapamil can be decreased when combined with Otamixaban.Investigational
OtiloniumThe risk or severity of hypotension can be increased when Verapamil is combined with Otilonium.Experimental, Investigational
OuabainVerapamil may increase the atrioventricular blocking (AV block) activities of Ouabain.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Verapamil.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Verapamil.Approved
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Verapamil.Approved
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Verapamil.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Verapamil is combined with Oxycodone.Approved, Illicit, Investigational
OxyfedrineVerapamil may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineVerapamil may decrease the vasoconstricting activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Verapamil.Approved, Vet Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Verapamil.Investigational
PalbociclibThe serum concentration of Verapamil can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidonePaliperidone may increase the antihypertensive activities of Verapamil.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Verapamil.Approved, Investigational
PanobinostatThe metabolism of Panobinostat can be decreased when combined with Verapamil.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Verapamil.Approved
PapaverineThe risk or severity of adverse effects can be increased when Verapamil is combined with Papaverine.Approved, Investigational
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Verapamil.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Verapamil.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Verapamil.Approved
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Verapamil.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Verapamil.Approved, Investigational
ParoxetineThe metabolism of Verapamil can be decreased when combined with Paroxetine.Approved, Investigational
PasireotideVerapamil may increase the bradycardic activities of Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Verapamil.Approved
Peginterferon alfa-2bThe serum concentration of Verapamil can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Verapamil.Approved, Investigational
PentamidineThe metabolism of Pentamidine can be decreased when combined with Verapamil.Approved, Investigational
PentobarbitalThe metabolism of Verapamil can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Verapamil.Approved, Investigational
PerampanelThe metabolism of Perampanel can be decreased when combined with Verapamil.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Verapamil.Approved, Investigational
PerindoprilThe metabolism of Verapamil can be decreased when combined with Perindopril.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Verapamil.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Verapamil.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Verapamil.Approved
PeruvosideVerapamil may increase the atrioventricular blocking (AV block) activities of Peruvoside.Experimental
PethidineThe metabolism of Pethidine can be decreased when combined with Verapamil.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Verapamil.Withdrawn
PhendimetrazineVerapamil may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Verapamil.Approved
PhenobarbitalThe metabolism of Verapamil can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxybenzaminePhenoxybenzamine may increase the antihypertensive activities of Verapamil.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Verapamil.Approved, Investigational
PhentolaminePhentolamine may increase the antihypertensive activities of Verapamil.Approved
Phenyl aminosalicylateVerapamil may increase the anticoagulant activities of Phenyl aminosalicylate.Approved
PhenylephrineVerapamil may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineVerapamil may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Verapamil can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe metabolism of Verapamil can be decreased when combined with Phosphoramidon.Experimental
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Verapamil.Approved, Investigational
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Verapamil.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Verapamil.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Verapamil.Approved
PinaveriumThe risk or severity of hypotension can be increased when Verapamil is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Verapamil.Approved, Investigational
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Verapamil.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Verapamil.Approved, Investigational
PiperaquineThe metabolism of Piperaquine can be decreased when combined with Verapamil.Approved, Investigational
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Verapamil.Approved, Investigational
PirbuterolVerapamil may decrease the vasoconstricting activities of Pirbuterol.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Verapamil.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Verapamil.Approved, Investigational
PizotifenVerapamil may increase the antihypertensive activities of Pizotifen.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Verapamil.Experimental
PodofiloxThe metabolism of Podofilox can be decreased when combined with Verapamil.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Verapamil.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Verapamil.Approved, Investigational
Poractant alfaVerapamil may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe metabolism of Verapamil can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the orthostatic hypotensive activities of Verapamil.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Verapamil.Approved, Investigational
PrasteroneThe metabolism of Prasterone can be decreased when combined with Verapamil.Approved, Investigational, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Verapamil.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Verapamil.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Verapamil.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
PrazosinPrazosin may increase the antihypertensive activities of Verapamil.Approved
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Verapamil.Approved, Vet Approved
PrednisoneThe metabolism of Prednisone can be decreased when combined with Verapamil.Approved, Vet Approved
PrenalterolVerapamil may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Verapamil is combined with Prenylamine.Withdrawn
PrimaquineThe metabolism of Primaquine can be decreased when combined with Verapamil.Approved
PrimidoneThe metabolism of Verapamil can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe metabolism of Verapamil can be decreased when combined with Prinomastat.Investigational
ProcaterolVerapamil may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Verapamil.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Verapamil.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Verapamil.Approved
PromazinePromazine may increase the antihypertensive activities of Verapamil.Approved, Vet Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Verapamil.Approved
PropericiazineVerapamil may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazinePropiomazine may increase the antihypertensive activities of Verapamil.Approved
PropiverineVerapamil may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropofolThe metabolism of Propofol can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Verapamil.Approved, Investigational
ProscillaridinVerapamil may increase the atrioventricular blocking (AV block) activities of Proscillaridin.Experimental
ProtokylolVerapamil may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Verapamil.Approved
PseudoephedrineVerapamil may decrease the vasoconstricting activities of Pseudoephedrine.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Verapamil.Approved, Investigational
PyrimethamineThe metabolism of Verapamil can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Verapamil.Experimental
QuazepamThe serum concentration of Verapamil can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineQuetiapine may increase the antihypertensive activities of Verapamil.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Verapamil.Approved, Investigational
QuinaprilThe metabolism of Verapamil can be decreased when combined with Quinapril.Approved, Investigational
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Verapamil.Approved, Investigational
QuinineThe metabolism of Quinine can be decreased when combined with Verapamil.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Verapamil.Approved, Investigational
RacecadotrilThe metabolism of Verapamil can be decreased when combined with Racecadotril.Investigational
RacepinephrineVerapamil may increase the antihypertensive activities of Racepinephrine.Approved
RactopamineVerapamil may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Verapamil.Experimental
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Verapamil.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Verapamil.Approved, Investigational
RamiprilThe metabolism of Verapamil can be decreased when combined with Ramipril.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Verapamil.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Verapamil.Approved
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Verapamil.Approved, Investigational
RegorafenibRegorafenib may increase the bradycardic activities of Verapamil.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Verapamil.Approved
RemikirenThe metabolism of Verapamil can be decreased when combined with Remikiren.Approved
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Verapamil.Approved, Investigational
ReproterolVerapamil may decrease the vasoconstricting activities of Reproterol.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Verapamil.Approved, Investigational
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Verapamil.Approved
RifabutinThe metabolism of Verapamil can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Verapamil can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Verapamil can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Verapamil.Approved, Investigational
RilmenidineVerapamil may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Verapamil.Approved
RimiterolVerapamil may decrease the vasoconstricting activities of Rimiterol.Experimental
RimonabantThe metabolism of Rimonabant can be decreased when combined with Verapamil.Approved, Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Verapamil.Approved
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Verapamil.Approved, Investigational
RitobegronVerapamil may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineVerapamil may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RitonavirThe metabolism of Verapamil can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe metabolism of Verapamil can be decreased when combined with Rivaroxaban.Approved
RivastigmineVerapamil may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Verapamil.Approved, Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Verapamil.Approved, Investigational
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Verapamil.Approved, Investigational
RomifidineVerapamil may decrease the vasoconstricting activities of Romifidine.Vet Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Verapamil.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Verapamil.Approved
RosiglitazoneThe metabolism of Verapamil can be decreased when combined with Rosiglitazone.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Verapamil.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Verapamil.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Verapamil.Approved, Investigational, Withdrawn
RucaparibThe metabolism of Rucaparib can be decreased when combined with Verapamil.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Verapamil.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Verapamil.Approved
S-3304The metabolism of Verapamil can be decreased when combined with S-3304.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Verapamil.Approved
SafinamideThe metabolism of Safinamide can be decreased when combined with Verapamil.Approved, Investigational
SalbutamolVerapamil may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Verapamil.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Verapamil.Approved, Investigational, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Verapamil.Approved
SaquinavirThe metabolism of Verapamil can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Verapamil can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Verapamil.Approved
SecobarbitalThe metabolism of Verapamil can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Verapamil is combined with Seletracetam.Investigational
SelexipagThe metabolism of Selexipag can be decreased when combined with Verapamil.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Verapamil.Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Verapamil.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Verapamil.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Verapamil.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Verapamil.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Verapamil.Approved, Illicit, Investigational, Withdrawn
SildenafilSildenafil may increase the hypotensive activities of Verapamil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Verapamil.Approved
SiltuximabThe serum concentration of Verapamil can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Verapamil can be increased when it is combined with Simeprevir.Approved
SimvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Verapamil is combined with Simvastatin.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Verapamil.Experimental
SirolimusThe metabolism of Sirolimus can be decreased when combined with Verapamil.Approved, Investigational
SitagliptinThe metabolism of Verapamil can be decreased when combined with Sitagliptin.Approved, Investigational
SivelestatThe metabolism of Verapamil can be decreased when combined with Sivelestat.Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Verapamil.Approved
SolabegronVerapamil may decrease the vasoconstricting activities of Solabegron.Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Verapamil.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Verapamil.Approved, Investigational
SorafenibThe metabolism of Sorafenib can be decreased when combined with Verapamil.Approved, Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Verapamil.Approved
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Verapamil.Approved
SpiraprilThe metabolism of Verapamil can be decreased when combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Verapamil.Approved
St. John's WortThe serum concentration of Verapamil can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Verapamil can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Verapamil.Approved, Investigational
SufentanilThe metabolism of Sufentanil can be decreased when combined with Verapamil.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Verapamil.Approved
SulfadiazineThe metabolism of Verapamil can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Verapamil.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Verapamil.Approved
SulfisoxazoleThe metabolism of Verapamil can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Verapamil.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Verapamil.Approved, Investigational
SynephrineVerapamil may decrease the vasoconstricting activities of Synephrine.Experimental
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Verapamil.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Verapamil.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Verapamil.Approved, Investigational
TadalafilTadalafil may increase the hypotensive activities of Verapamil.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Verapamil.Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Verapamil.Approved
TamsulosinTamsulosin may increase the antihypertensive activities of Verapamil.Approved, Investigational
TasosartanThe metabolism of Tasosartan can be decreased when combined with Verapamil.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Verapamil.Experimental
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Verapamil.Approved, Investigational
TelaprevirThe metabolism of Verapamil can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Verapamil can be increased when it is combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Verapamil is combined with Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Verapamil.Approved, Investigational
TemocaprilThe metabolism of Verapamil can be decreased when combined with Temocapril.Experimental, Investigational
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Verapamil.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Verapamil.Approved
Tenofovir disoproxilThe metabolism of Verapamil can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerazosinTerazosin may increase the antihypertensive activities of Verapamil.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the orthostatic hypotensive activities of Verapamil.Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Verapamil.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Verapamil.Approved, Withdrawn
TeriflunomideThe serum concentration of Verapamil can be decreased when it is combined with Teriflunomide.Approved
TerodilineThe risk or severity of hypotension can be increased when Verapamil is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Verapamil.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Verapamil.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Verapamil.Approved, Investigational
Testosterone cypionateThe metabolism of Testosterone cypionate can be decreased when combined with Verapamil.Approved
Testosterone enanthateThe metabolism of Testosterone enanthate can be decreased when combined with Verapamil.Approved
Testosterone propionateThe metabolism of Testosterone propionate can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe metabolism of Testosterone undecanoate can be decreased when combined with Verapamil.Approved, Investigational
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Verapamil.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of hypotension can be increased when Verapamil is combined with Tetrahydropalmatine.Investigational
TetryzolineVerapamil may decrease the vasoconstricting activities of Tetryzoline.Approved
TezacaftorThe metabolism of Tezacaftor can be decreased when combined with Verapamil.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Verapamil.Approved, Investigational, Withdrawn
TheophyllineTheophylline may increase the hypotensive activities of Verapamil.Approved
ThiamylalThe metabolism of Verapamil can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Verapamil can be increased when combined with Thiopental.Approved, Vet Approved
ThioproperazineThioproperazine may increase the antihypertensive activities of Verapamil.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Verapamil.Approved, Withdrawn
ThiorphanThe metabolism of Verapamil can be decreased when combined with Thiorphan.Experimental
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Verapamil.Approved, Investigational
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Verapamil.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Verapamil.Approved, Investigational
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Verapamil.Approved
TiclopidineThe metabolism of Verapamil can be decreased when combined with Ticlopidine.Approved
TimololTimolol may increase the orthostatic hypotensive activities of Verapamil.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Verapamil.Approved, Investigational
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Verapamil.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Verapamil.Approved
TipranavirThe metabolism of Verapamil can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Verapamil.Approved, Investigational
TocilizumabThe serum concentration of Verapamil can be decreased when it is combined with Tocilizumab.Approved
TocofersolanThe metabolism of Tocofersolan can be decreased when combined with Verapamil.Approved
TocopherolThe metabolism of Tocopherol can be decreased when combined with Verapamil.Approved, Investigational
TofacitinibTofacitinib may increase the bradycardic activities of Verapamil.Approved, Investigational
TolazolineTolazoline may increase the antihypertensive activities of Verapamil.Approved, Vet Approved
TolbutamideThe metabolism of Verapamil can be decreased when combined with Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Verapamil.Approved, Withdrawn
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Verapamil.Experimental
Tolfenamic AcidThe risk or severity of hypotension can be increased when Verapamil is combined with Tolfenamic Acid.Approved, Investigational
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Verapamil.Approved, Investigational, Vet Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Verapamil.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Verapamil.Approved
TopiramateThe metabolism of Verapamil can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Verapamil can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Verapamil.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Verapamil.Approved
ToremifeneThe metabolism of Toremifene can be decreased when combined with Verapamil.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Verapamil.Approved, Investigational
TramadolThe metabolism of Tramadol can be decreased when combined with Verapamil.Approved, Investigational
TrandolaprilThe metabolism of Verapamil can be decreased when combined with Trandolapril.Approved
TranilastThe risk or severity of hypotension can be increased when Verapamil is combined with Tranilast.Approved, Investigational
TranylcypromineThe metabolism of Verapamil can be decreased when combined with Tranylcypromine.Approved, Investigational
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Verapamil.Approved, Investigational
TrazodoneTrazodone may increase the antihypertensive activities of Verapamil.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Verapamil.Approved, Investigational, Nutraceutical
TretoquinolVerapamil may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Verapamil.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Verapamil.Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Verapamil.Approved, Investigational
TrifluoperazineTrifluoperazine may increase the antihypertensive activities of Verapamil.Approved, Investigational
TrimazosinTrimazosin may increase the antihypertensive activities of Verapamil.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Verapamil is combined with Trimebutine.Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Verapamil.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Verapamil.Approved, Vet Approved
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Verapamil.Approved, Investigational
TrimipramineTrimipramine may increase the antihypertensive activities of Verapamil.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Verapamil.Investigational, Withdrawn
Trolamine salicylateVerapamil may increase the anticoagulant activities of Trolamine salicylate.Approved
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Verapamil.Approved
TulobuterolVerapamil may decrease the vasoconstricting activities of Tulobuterol.Investigational
UbenimexThe metabolism of Verapamil can be decreased when combined with Ubenimex.Experimental, Investigational
UdenafilUdenafil may increase the hypotensive activities of Verapamil.Approved, Investigational
UlinastatinThe metabolism of Verapamil can be decreased when combined with Ulinastatin.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Verapamil.Approved
UrapidilUrapidil may increase the antihypertensive activities of Verapamil.Investigational
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Verapamil.Approved, Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Verapamil.Approved, Investigational, Withdrawn
Valproic AcidThe metabolism of Verapamil can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Verapamil can be decreased when combined with Valsartan.Approved, Investigational
VandetanibThe metabolism of Vandetanib can be decreased when combined with Verapamil.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Verapamil.Investigational
VardenafilVardenafil may increase the hypotensive activities of Verapamil.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Verapamil.Approved, Investigational
VemurafenibThe serum concentration of Verapamil can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Verapamil.Approved, Investigational
VenlafaxineThe metabolism of Verapamil can be decreased when combined with Venlafaxine.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Verapamil.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Verapamil.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Verapamil.Approved
VildagliptinThe metabolism of Verapamil can be decreased when combined with Vildagliptin.Approved, Investigational
VinblastineThe metabolism of Vinblastine can be decreased when combined with Verapamil.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Verapamil.Approved, Investigational
VincristineThe metabolism of Vincristine can be decreased when combined with Verapamil.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Verapamil.Approved, Investigational
VinflunineThe metabolism of Vinflunine can be decreased when combined with Verapamil.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Verapamil.Approved, Investigational
VinpocetineThe risk or severity of hypotension can be increased when Verapamil is combined with Vinpocetine.Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Verapamil.Approved, Investigational
VoriconazoleThe metabolism of Verapamil can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Verapamil.Approved, Investigational
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Verapamil.Approved, Investigational
WarfarinThe metabolism of Warfarin can be decreased when combined with Verapamil.Approved
WIN 55212-2The risk or severity of hypotension can be increased when Verapamil is combined with WIN 55212-2.Experimental
WortmanninThe therapeutic efficacy of Wortmannin can be increased when used in combination with Verapamil.Experimental
XamoterolVerapamil may decrease the vasoconstricting activities of Xamoterol.Experimental
XimelagatranThe metabolism of Verapamil can be decreased when combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineVerapamil may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolineVerapamil may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
YohimbineThe metabolism of Yohimbine can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe metabolism of Verapamil can be decreased when combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Verapamil.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Verapamil.Approved, Investigational
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Verapamil.Approved, Illicit, Investigational
ZiconotideThe risk or severity of hypotension can be increased when Verapamil is combined with Ziconotide.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Verapamil.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Verapamil.Approved, Investigational, Withdrawn
ZiprasidoneZiprasidone may increase the antihypertensive activities of Verapamil.Approved
ZofenoprilThe metabolism of Verapamil can be decreased when combined with Zofenopril.Experimental
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Verapamil.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Verapamil.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Verapamil.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Verapamil.Approved
ZotepineThe metabolism of Zotepine can be decreased when combined with Verapamil.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Verapamil can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Verapamil.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid natural licorice.
  • Avoid taking with grapefruit juice.
  • Take with food.

References

Synthesis Reference

Philippe Baudier, Arthur De Boeck, Jacques Fossion, "Novel galenic forms of verapamil, their preparation and medicines containing said novel galenic forms." U.S. Patent US4859469, issued April, 1987.

US4859469
General References
  1. Bellamy WT: P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol. 1996;36:161-83. [PubMed:8725386]
External Links
Human Metabolome Database
HMDB0001850
KEGG Drug
D02356
KEGG Compound
C07188
PubChem Compound
2520
PubChem Substance
46508158
ChemSpider
2425
BindingDB
81939
ChEBI
77733
ChEMBL
CHEMBL6966
Therapeutic Targets Database
DAP000040
PharmGKB
PA451868
IUPHAR
2406
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Verapamil
ATC Codes
C08DA51 — Verapamil, combinationsC08DA01 — VerapamilC09BB10 — Trandolapril and verapamil
AHFS Codes
  • 24:28.92 — Miscellaneous Calcium-channel Blocking Agents
FDA label
Download (1.9 MB)
MSDS
Download (73.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableCrohn's Disease (CD)1
1CompletedNot AvailableDrug Dependence1
1CompletedNot AvailableHealthy Volunteers1
1CompletedBasic ScienceDrug Drug Interactions / Healthy Volunteers1
1CompletedBasic ScienceDrug-Drug Interaction (DDI) / Healthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers / Pharmacokinetics of ASP015K1
1CompletedBasic SciencePharmacokinetics1
1CompletedDiagnosticChronic Subjective Dizziness / Vestibular Migraine1
1CompletedOtherDrug-induced QT Interval Prolongation / Pharmacodynamics / Pharmacokinetics1
1CompletedOtherHealthy Volunteers1
1CompletedTreatmentDrug-induced Surface ECG Changes1
1CompletedTreatmentHealthy Volunteers4
1CompletedTreatmentStroke, Ischemic1
1CompletedTreatmentType 2 Diabetes Mellitus1
1RecruitingBasic ScienceCardiovascular System Disease / Drug-Related Side Effects and Adverse Reactions1
1RecruitingTreatmentCD30-Positive Neoplastic Cells Present / Recurrent Hodgkin Lymphoma / Refractory Hodgkin Lymphoma1
1RecruitingTreatmentStroke, Ischemic2
1WithdrawnTreatmentStroke, Ischemic1
1, 2CompletedHealth Services ResearchHealthy Volunteers1
1, 2RecruitingTreatmentPolyps, Nasal / Sinusitis1
1, 2TerminatedTreatmentKnee Osteoarthritis (Knee OA)1
2Active Not RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
2CompletedTreatmentBrain Cancer / Cancers / Meningiomas1
2CompletedTreatmentDravet Syndrome1
2, 3CompletedTreatmentCluster Headache1
2, 3RecruitingTreatmentVentricular Arrythmias1
3CompletedTreatmentArrythmias / Cardiovascular Disease (CVD) / Heart Diseases / Nonvalvular Atrial Fibrillation1
3CompletedTreatmentBMI >30 kg/m2 / High Blood Pressure (Hypertension)1
3CompletedTreatmentMania1
3CompletedTreatmentNonvalvular Atrial Fibrillation1
3TerminatedTreatmentHeart Failure, Unspecified / Nonvalvular Atrial Fibrillation1
4CompletedPreventionRenal Stones1
4CompletedTreatmentAcute Myocardial Infarction (AMI) / Percutaneous Coronary Intervention1
4CompletedTreatmentBMI >30 kg/m2 / General Surgery / Hypoglycemia1
4CompletedTreatmentDiabetes Mellitus (DM) / High Blood Pressure (Hypertension)1
4CompletedTreatmentDiabetes Mellitus (DM) / High Blood Pressure (Hypertension) / Proteinuria1
4CompletedTreatmentHeart Disease, Ischemic1
4CompletedTreatmentHigh Blood Pressure (Hypertension)2
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Metabolic Syndromes1
4CompletedTreatmentMarfan Syndrome1
4CompletedTreatmentParoxysmal Supraventricular Tachycardia1
4CompletedTreatmentRapid Ventricular Response Atrial Fibrillation1
4RecruitingHealth Services ResearchCerebral Vasospasm1
4RecruitingTreatmentReversible cerebral vasoconstriction syndrome1
4TerminatedPreventionKeloid Scars1
4Unknown StatusTreatmentCongestive Cardiomyopathy1
4Unknown StatusTreatmentHeart Failure With Reduced Ejection Fraction (HFrEF) / Myocardial Diseases / Prophylaxis of cardiomyopathy1
Not AvailableCompletedNot AvailableCoronary Heart Disease (CHD) / Verapamil Toxicity1
Not AvailableCompletedNot AvailableErectile Dysfunction (ED)1
Not AvailableCompletedTreatmentArrythmias / Nonvalvular Atrial Fibrillation1
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus1
Not AvailableRecruitingTreatmentNonvalvular Atrial Fibrillation1
Not AvailableTerminatedTreatmentPolyps, Nasal / Sinusitis1
Not AvailableUnknown StatusTreatmentEpilepsies / Seizures1
Not AvailableWithdrawnTreatmentCatamenial Epilepsy1

Pharmacoeconomics

Manufacturers
  • Mylan pharmaceuticals inc
  • Elan drug delivery inc
  • Gd searle llc
  • Fsc laboratories inc
  • Abraxis pharmaceutical products
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • International medication system
  • Luitpold pharmaceuticals inc
  • Marsam pharmaceuticals llc
  • Smith and nephew solopak div smith and nephew
  • Solopak medical products inc
  • Ranbaxy laboratories inc
  • Glenmark generics ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Par pharmaceutical inc
  • Pliva inc
  • Actavis elizabeth llc
  • Heritage pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Sandoz inc
  • Warner chilcott div warner lambert co
  • Watson laboratories inc
Packagers
  • Abbott Laboratories Ltd.
  • Advanced Pharmaceutical Services Inc.
  • Alza Corp.
  • Amerisource Health Services Corp.
  • Apotheca Inc.
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • BASF Corp.
  • Cardinal Health
  • Caremark LLC
  • Comprehensive Consultant Services Inc.
  • Copley Chemical Co.
  • Dee Stevens and Son Feeder
  • Dept Health Central Pharmacy
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Duramed
  • Elan Pharmaceuticals Inc.
  • FSC Laboratories
  • GD Searle LLC
  • General Injectables and Vaccines Inc.
  • Glenmark Generics Ltd.
  • Golden State Medical Supply Inc.
  • Group Health Cooperative
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Hospira Inc.
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Medisca Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pfizer Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmacia Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prescript Pharmaceuticals
  • Ranbaxy Laboratories
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Sandhills Packaging Inc.
  • Schwarz Pharma Inc.
  • Southwood Pharmaceuticals
  • Talbert Medical Management Corp.
  • Tya Pharmaceuticals
  • UDL Laboratories
  • United Research Laboratories Inc.
  • Vangard Labs Inc.
  • Watson Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral80 mg
Tablet, extended releaseOral180 mg/1
Tablet, extended releaseOral180 mg
Tablet, extended releaseOral240 mg/1
TabletOral120 mg
Tablet, extended releaseOral120 mg
Tablet, extended releaseOral240 mg
Tablet, extended releaseOral
Tablet, film coated, extended releaseOral
Capsule, extended releaseOral120 mg/1
Capsule, extended releaseOral180 mg/1
Capsule, extended releaseOral240 mg/1
InjectionIntravenous2.5 mg/mL
Injection, solutionIntravenous2.5 mg/mL
TabletOral120 mg/1
TabletOral240 mg/1
TabletOral40 mg/1
TabletOral80 mg/1
Tablet, extended releaseOral120 mg/1
Tablet, extended releaseOral240 mg/301
Tablet, film coatedOral120 mg/1
Tablet, film coatedOral40 mg/1
Tablet, film coatedOral80 mg/1
Tablet, film coated, extended releaseOral120 mg/1
Tablet, film coated, extended releaseOral180 mg/1
Tablet, film coated, extended releaseOral240 mg/1
LiquidIntravenous2.5 mg
SolutionIntravenous2.5 mg
Capsule, delayed release pelletsOral120 mg/1
Capsule, delayed release pelletsOral180 mg/1
Capsule, delayed release pelletsOral240 mg/1
Capsule, delayed release pelletsOral360 mg/1
Capsule, extended releaseOral120 mg
Capsule, extended releaseOral180 mg
Capsule, extended releaseOral240 mg
Capsule, extended releaseOral100 mg/1
Capsule, extended releaseOral200 mg/1
Capsule, extended releaseOral300 mg/1
Prices
Unit descriptionCostUnit
Verelan 360 mg 24 Hour Capsule6.82USD capsule
Verelan 360 mg cap pellet6.73USD pellet
Verelan pm 300 mg cap pellet5.87USD pellet
Verelan 240 mg 24 Hour Capsule4.76USD capsule
Verelan 240 mg cap pellet4.58USD pellet
Verelan 180 mg 24 Hour Capsule4.22USD capsule
Verelan 180 mg cap pellet4.06USD pellet
Verelan pm 200 mg cap pellet4.04USD pellet
Verelan 120 mg cap pellet3.87USD pellet
Verapamil HCl CR 300 mg 24 Hour Capsule3.82USD capsule
Isoptin sr 240 mg tablet3.32USD tablet
Verapamil hcl powder3.24USD g
Calan SR 240 mg Controlled Release Tabs3.15USD tab
Isoptin SR 240 mg Controlled Release Tabs3.14USD tab
Verelan pm 100 mg cap pellet3.13USD pellet
Calan sr 240 mg caplet3.09USD caplet
Covera-HS 240 mg 24 Hour tablet3.09USD tablet
Covera-hs 240 mg tablet sa2.97USD tablet
Isoptin sr 180 mg tablet2.9USD tablet
Calan SR 180 mg Controlled Release Tabs2.8USD tab
Isoptin SR 180 mg Controlled Release Tabs2.74USD tab
Calan sr 180 mg caplet2.7USD caplet
Verapamil HCl CR 200 mg 24 Hour Capsule2.62USD capsule
Isoptin sr 120 mg tablet2.29USD tablet
Calan SR 120 mg Controlled Release Tabs2.27USD tab
Covera-HS 180 mg 24 Hour tablet2.2USD tablet
Isoptin SR 120 mg Controlled Release Tabs2.16USD tab
Calan sr 120 mg caplet2.13USD caplet
Covera-hs 180 mg tablet sa2.11USD tablet
Verapamil HCl CR 360 mg 24 Hour Capsule2.1USD capsule
Verapamil HCl CR 100 mg 24 Hour Capsule2.04USD capsule
Isoptin Sr 240 mg Sustained-Release Tablet2.03USD tablet
Calan sr 240 mg caplet sa1.77USD caplet
Verapamil HCl CR 240 mg 24 Hour Capsule1.69USD capsule
Verapamil HCl CR 240 mg Controlled Release Tabs1.6USD tab
Calan 120 mg tablet1.56USD tablet
Isoptin Sr 180 mg Sustained-Release Tablet1.52USD tablet
Verapamil HCl CR 180 mg 24 Hour Capsule1.5USD capsule
Calan sr 180 mg caplet sa1.46USD caplet
Verapamil HCl CR 120 mg 24 Hour Capsule1.43USD capsule
Verapamil HCl CR 180 mg Controlled Release Tabs1.41USD tab
Isoptin Sr 120 mg Sustained-Release Tablet1.34USD tablet
Calan 80 mg tablet1.25USD tablet
Verapamil 2.5 mg/ml vial1.18USD ml
Verapamil HCl CR 120 mg Controlled Release Tabs1.12USD tab
Apo-Verap Sr 240 mg Sustained-Release Tablet0.91USD tablet
Mylan-Verapamil Sr 240 mg Sustained-Release Tablet0.91USD tablet
Novo-Veramil Sr 240 mg Sustained-Release Tablet0.91USD tablet
Pms-Verapamil Sr 240 mg Sustained-Release Tablet0.91USD tablet
Calan 40 mg tablet0.76USD tablet
Apo-Verap Sr 120 mg Sustained-Release Tablet0.72USD tablet
Mylan-Verapamil Sr 120 mg Sustained-Release Tablet0.72USD tablet
Verapamil HCl 120 mg tablet0.71USD tablet
Apo-Verap Sr 180 mg Sustained-Release Tablet0.69USD tablet
Mylan-Verapamil Sr 180 mg Sustained-Release Tablet0.69USD tablet
Verapamil HCl 80 mg tablet0.56USD tablet
Apo-Verap 120 mg Tablet0.45USD tablet
Mylan-Verapamil 120 mg Tablet0.45USD tablet
Nu-Verap 120 mg Tablet0.45USD tablet
Verapamil 120 mg tablet0.39USD tablet
Verapamil 80 mg tablet0.31USD tablet
Verapamil HCl 40 mg tablet0.29USD tablet
Apo-Verap 80 mg Tablet0.29USD tablet
Mylan-Verapamil 80 mg Tablet0.29USD tablet
Nu-Verap 80 mg Tablet0.29USD tablet
Verapamil 40 mg tablet0.28USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5785994No1992-10-222009-10-22Us
US6096339No1997-04-042017-04-04Us

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)< 25 °CPhysProp
boiling point (°C)243-246 °C at 1.00E-02 mm HgPhysProp
water solubility4.47 mg/LNot Available
logP3.79HANSCH,C ET AL. (1995)
Caco2 permeability-4.58ADME Research, USCD
pKa8.92SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.00394 mg/mLALOGPS
logP5.23ALOGPS
logP5.04ChemAxon
logS-5.1ALOGPS
pKa (Strongest Basic)9.68ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area63.95 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity132.65 m3·mol-1ChemAxon
Polarizability51.7 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9371
Blood Brain Barrier+0.6323
Caco-2 permeable+0.738
P-glycoprotein substrateSubstrate0.7874
P-glycoprotein inhibitor IInhibitor0.9056
P-glycoprotein inhibitor IIInhibitor0.855
Renal organic cation transporterInhibitor0.6259
CYP450 2C9 substrateNon-substrate0.8029
CYP450 2D6 substrateNon-substrate0.8706
CYP450 3A4 substrateSubstrate0.7657
CYP450 1A2 substrateNon-inhibitor0.9553
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9181
Ames testNon AMES toxic0.8393
CarcinogenicityNon-carcinogens0.6463
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.4137 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7687
hERG inhibition (predictor II)Inhibitor0.8188
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0udi-3519000000-b5e0b9e0caac5cb57222
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-004l-0702900000-6a46ea2d5eed6d8b01eb
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-0006-4109800000-80d342090a0be3344e82
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-054w-0954400000-2def387c7c93ab211423
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, PositiveLC-MS/MSsplash10-0a4i-0000900000-4cde9a4b3a4f83d16afc
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, PositiveLC-MS/MSsplash10-0a4i-0000900000-980b47834e505d54a0e6
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, PositiveLC-MS/MSsplash10-066r-0902800000-ae024239c46b33917426
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, PositiveLC-MS/MSsplash10-014i-0901000000-81d1159b3102cff76218
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, PositiveLC-MS/MSsplash10-014i-0900000000-d9c344fee7b45b4030e6
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-0gb9-0914000000-070bdb975910e9aae99c
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-03di-0390000000-f41d80462c5d06c4f001
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-0097-2980000000-9a2ab0bcab33f7eaac6b
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-0uxr-0900000000-252a9989a8511cb2db80
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-0f79-0900000000-4fd6ca2c6c19c3bbf8f0
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0000900000-4365a47b2dc2f86bb272
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0000900000-e6a2b357160bf5b92c22
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-066r-0902400000-d8eac2ccd0a767c7e432
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0901000000-688f3c2345c5d9ccb8a5
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0900000000-cd09f8a2be876936f662
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uxr-0918000000-76641dd6dbc5cb05e79a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0000900000-05ea95eb1f39b6515212
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-066r-0902600000-a675e624692c25472ce8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0901000000-70d820628d2613557239
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0gb9-0900000000-e3ca24cf75d574df08a8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uyi-0900000000-f3a9fa002c56d3e5689a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0zg0-2900000000-101e077b890671063633
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0000900000-84b4516ac84e6912cc15
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-066r-0902600000-bc1701c307e45ee4dcd7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0901000000-6fbdab598bcb6147a4bf
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0gb9-0900000000-ce61116806eaa908681c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uxr-0900000000-ad3f25e02a7c8e66fb6a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0zgr-2900000000-792b9009086561f6c398
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uxr-0918000000-e7a5a3f8c88dc40683fd
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4i-0000900000-4cde9a4b3a4f83d16afc
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4i-0000900000-9a5c5240148f82cc6add
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-066r-0902800000-ae024239c46b33917426
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-014i-0901000000-81d1159b3102cff76218
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-014i-0900000000-2411d65dfe09741dde81
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-0gb9-0914000000-0463345a8ab0de7aa99e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0900000000-42074ab645b7af0ef79f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0zgi-0900000000-20360f78435d5f482709
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uxr-0819000000-7f68ebd6e344adf12101
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uxr-0918000000-d3727bbe601b80eabfb3
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0100900000-0a928f78000f291f031d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-066r-0902600000-40f800e4a364d9ca214c
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0gb9-0900000000-4dea228d69d59705fc18
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0500900000-c0bc440571b30d4b5b27
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-066r-0900300000-47a59c15bdbcbc62d6c6
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylbutylamines. These are compounds containing a phenylbutylamine moiety, which consists of a phenyl group substituted at the fourth carbon by an butan-1-amine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylbutylamines
Direct Parent
Phenylbutylamines
Alternative Parents
Dimethoxybenzenes / Phenylpropanes / Phenethylamines / Phenoxy compounds / Anisoles / Aralkylamines / Alkyl aryl ethers / Trialkylamines / Nitriles / Organopnictogen compounds
show 1 more
Substituents
Phenylbutylamine / Dimethoxybenzene / O-dimethoxybenzene / Phenethylamine / Phenylpropane / Anisole / Phenol ether / Phenoxy compound / Methoxybenzene / Alkyl aryl ether
show 14 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
tertiary amino compound, aromatic ether, nitrile, polyether (CHEBI:77733)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1C
Uniprot ID
Q13936
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1C
Molecular Weight
248974.1 Da
References
  1. Dilmac N, Hilliard N, Hockerman GH: Molecular determinants of frequency dependence and Ca2+ potentiation of verapamil block in the pore region of Cav1.2. Mol Pharmacol. 2004 Nov;66(5):1236-47. Epub 2004 Jul 30. [PubMed:15286207]
  2. Morel N, Buryi V, Feron O, Gomez JP, Christen MO, Godfraind T: The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits. Br J Pharmacol. 1998 Nov;125(5):1005-12. [PubMed:9846638]
  3. Patel MK, Clunn GF, Lymn JS, Austin O, Hughes AD: Effect of serum withdrawal on the contribution of L-type calcium channels (CaV1.2) to intracellular Ca2+ responses and chemotaxis in cultured human vascular smooth muscle cells. Br J Pharmacol. 2005 Jul;145(6):811-7. [PubMed:15880143]
  4. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1D
Uniprot ID
Q01668
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1D
Molecular Weight
245138.75 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1F
Uniprot ID
O60840
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1F
Molecular Weight
220675.9 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1S
Uniprot ID
Q13698
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1S
Molecular Weight
212348.1 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB1
Uniprot ID
Q02641
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-1
Molecular Weight
65712.995 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB2
Uniprot ID
Q08289
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-2
Molecular Weight
73579.925 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB3
Uniprot ID
P54284
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-3
Molecular Weight
54531.425 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB4
Uniprot ID
O00305
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-4
Molecular Weight
58168.625 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1I
Uniprot ID
Q9P0X4
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1I
Molecular Weight
245100.8 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1G
Uniprot ID
O43497
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1G
Molecular Weight
262468.62 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  3. Freeze BS, McNulty MM, Hanck DA: State-dependent verapamil block of the cloned human Ca(v)3.1 T-type Ca(2+) channel. Mol Pharmacol. 2006 Aug;70(2):718-26. Epub 2006 May 12. [PubMed:16699084]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1B
Uniprot ID
Q00975
Uniprot Name
Voltage-dependent N-type calcium channel subunit alpha-1B
Molecular Weight
262493.84 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1A
Uniprot ID
O00555
Uniprot Name
Voltage-dependent P/Q-type calcium channel subunit alpha-1A
Molecular Weight
282362.39 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Duan JJ, Ma JH, Zhang PH, Wang XP, Zou AR, Tu DN: Verapamil blocks HERG channel by the helix residue Y652 and F656 in the S6 transmembrane domain. Acta Pharmacol Sin. 2007 Jul;28(7):959-67. [PubMed:17588331]
  2. Cheng HC, Incardona J, McCullough B: Isolated perfused and paced guinea pig heart to test for drug-induced changes of the QT interval. J Pharmacol Toxicol Methods. 2006 Nov-Dec;54(3):278-87. Epub 2006 Feb 28. [PubMed:16507347]
  3. Schneider J, Hauser R, Andreas JO, Linz K, Jahnel U: Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs. Eur J Pharmacol. 2005 Apr 4;512(1):53-60. [PubMed:15814090]
  4. Ridley JM, Dooley PC, Milnes JT, Witchel HJ, Hancox JC: Lidoflazine is a high affinity blocker of the HERG K(+)channel. J Mol Cell Cardiol. 2004 May;36(5):701-5. [PubMed:15135665]
  5. Shimizu W, Aiba T, Antzelevitch C: Specific therapy based on the genotype and cellular mechanism in inherited cardiac arrhythmias. Long QT syndrome and Brugada syndrome. Curr Pharm Des. 2005;11(12):1561-72. [PubMed:15892662]
  6. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the pr...
Gene Name
SCN5A
Uniprot ID
Q14524
Uniprot Name
Sodium channel protein type 5 subunit alpha
Molecular Weight
226937.475 Da
References
  1. Milberg P, Reinsch N, Osada N, Wasmer K, Monnig G, Stypmann J, Breithardt G, Haverkamp W, Eckardt L: Verapamil prevents torsade de pointes by reduction of transmural dispersion of repolarization and suppression of early afterdepolarizations in an intact heart model of LQT3. Basic Res Cardiol. 2005 Jul;100(4):365-71. Epub 2005 Jun 10. [PubMed:15944809]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity
Specific Function
This receptor is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage ...
Gene Name
KCNJ11
Uniprot ID
Q14654
Uniprot Name
ATP-sensitive inward rectifier potassium channel 11
Molecular Weight
43540.375 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Yamada S, Kane GC, Behfar A, Liu XK, Dyer RB, Faustino RS, Miki T, Seino S, Terzic A: Protection conferred by myocardial ATP-sensitive K+ channels in pressure overload-induced congestive heart failure revealed in KCNJ11 Kir6.2-null mutant. J Physiol. 2006 Dec 15;577(Pt 3):1053-65. Epub 2006 Oct 12. [PubMed:17038430]
  3. Shigeto M, Katsura M, Matsuda M, Ohkuma S, Kaku K: Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum. J Pharmacol Exp Ther. 2007 Jul;322(1):1-7. Epub 2007 Apr 4. [PubMed:17409272]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
  2. Brown NL, Sirugue O, Worcel M: The effects of some slow channel blocking drugs on high affinity serotonin uptake by rat brain synaptosomes. Eur J Pharmacol. 1986 Apr 9;123(1):161-5. [PubMed:2940099]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Curator comments
Inhibits receptor activity but shows little competition for binding. Likely an allosteric modulator.
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Shibata K, Hirasawa A, Foglar R, Ogawa S, Tsujimoto G: Effects of quinidine and verapamil on human cardiovascular alpha1-adrenoceptors. Circulation. 1998 Apr 7;97(13):1227-30. [PubMed:9570190]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Curator comments
Inhibits receptor activity but shows little competition for binding. Likely an allosteric modulator.
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Shibata K, Hirasawa A, Foglar R, Ogawa S, Tsujimoto G: Effects of quinidine and verapamil on human cardiovascular alpha1-adrenoceptors. Circulation. 1998 Apr 7;97(13):1227-30. [PubMed:9570190]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Curator comments
Inhibits receptor activity but shows little competition for binding. Likely an allosteric modulator.
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Shibata K, Hirasawa A, Foglar R, Ogawa S, Tsujimoto G: Effects of quinidine and verapamil on human cardiovascular alpha1-adrenoceptors. Circulation. 1998 Apr 7;97(13):1227-30. [PubMed:9570190]

Enzymes

Details
1. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  4. Flockhart Table - Indiana University [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  3. Flockhart Table - Indiana University [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C18
Uniprot ID
P33260
Uniprot Name
Cytochrome P450 2C18
Molecular Weight
55710.075 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Perloff MD, von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ: Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS. 2000 Jun 16;14(9):1287-9. [PubMed:10894301]
  2. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747]
  3. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60. [PubMed:10820137]
  4. Kawahara I, Kato Y, Suzuki H, Achira M, Ito K, Crespi CL, Sugiyama Y: Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems. Drug Metab Dispos. 2000 Oct;28(10):1238-43. [PubMed:10997946]
  5. Fujita R, Ishikawa M, Takayanagi M, Takayanagi Y, Sasaki K: Enhancement of doxorubicin activity in multidrug-resistant cells by mefloquine. Methods Find Exp Clin Pharmacol. 2000 Jun;22(5):281-4. [PubMed:11031728]
  6. Gao J, Murase O, Schowen RL, Aube J, Borchardt RT: A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001 Feb;18(2):171-6. [PubMed:11405287]
  7. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514]
  8. Leonessa F, Kim JH, Ghiorghis A, Kulawiec RJ, Hammer C, Talebian A, Clarke R: C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump. J Med Chem. 2002 Jan 17;45(2):390-8. [PubMed:11784143]
  9. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72. [PubMed:12134945]
  10. Zhang S, Morris ME: Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther. 2003 Mar;304(3):1258-67. [PubMed:12604704]
  11. Horie K, Tang F, Borchardt RT: Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm Res. 2003 Feb;20(2):161-8. [PubMed:12636153]
  12. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389]
  13. van der Sandt IC, Blom-Roosemalen MC, de Boer AG, Breimer DD: Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur J Pharm Sci. 2000 Sep;11(3):207-14. [PubMed:11042226]
  14. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465]
  15. Wang EJ, Casciano CN, Clement RP, Johnson WW: Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos. 2001 Aug;29(8):1080-3. [PubMed:11454724]
  16. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369]
  17. Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ, Scherman D: Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol. 1994 Oct 7;48(7):1528-30. [PubMed:7945455]
  18. Hait WN, Gesmonde JF, Murren JR, Yang JM, Chen HX, Reiss M: Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem Pharmacol. 1993 Jan 26;45(2):401-6. [PubMed:8094615]
  19. Pouliot JF, L'Heureux F, Liu Z, Prichard RK, Georges E: Reversal of P-glycoprotein-associated multidrug resistance by ivermectin. Biochem Pharmacol. 1997 Jan 10;53(1):17-25. [PubMed:8960059]
  20. Kuhnel JM, Perrot JY, Faussat AM, Marie JP, Schwaller MA: Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe. Leukemia. 1997 Jul;11(7):1147-55. [PubMed:9205004]
  21. Kim AE, Dintaman JM, Waddell DS, Silverman JA: Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther. 1998 Sep;286(3):1439-45. [PubMed:9732409]
  22. Bebawy M, Morris MB, Roufogalis BD: A continuous fluorescence assay for the study of P-glycoprotein-mediated drug efflux using inside-out membrane vesicles. Anal Biochem. 1999 Mar 15;268(2):270-7. [PubMed:10075817]
  23. Golstein PE, Boom A, van Geffel J, Jacobs P, Masereel B, Beauwens R: P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch. 1999 Apr;437(5):652-60. [PubMed:10087141]
  24. Jonsson O, Behnam-Motlagh P, Persson M, Henriksson R, Grankvist K: Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem Pharmacol. 1999 Dec 1;58(11):1801-6. [PubMed:10571255]
  25. Eagling VA, Profit L, Back DJ: Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol. 1999 Oct;48(4):543-52. [PubMed:10583025]
  26. Choi CH, Kim JH, Kim SH: Reversal of P-glycoprotein-mediated MDR by 5,7,3',4',5'-pentamethoxyflavone and SAR. Biochem Biophys Res Commun. 2004 Jul 30;320(3):672-9. [PubMed:15240100]
  27. Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol. 2004 Dec;143(7):856-64. Epub 2004 Oct 25. [PubMed:15504753]
  28. Hu K, Morris ME: Effects of benzyl-, phenethyl-, and alpha-naphthyl isothiocyanates on P-glycoprotein- and MRP1-mediated transport. J Pharm Sci. 2004 Jul;93(7):1901-11. [PubMed:15176077]
  29. Lee BH, Lee CO, Kwon MJ, Yi KY, Yoo SE, Choi SU: Differential effects of the optical isomers of KR30031 on cardiotoxicity and on multidrug resistance reversal activity. Anticancer Drugs. 2003 Feb;14(2):175-81. [PubMed:12569305]
  30. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103]
  31. Petri N, Tannergren C, Rungstad D, Lennernas H: Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm Res. 2004 Aug;21(8):1398-404. [PubMed:15359574]
  32. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10. [PubMed:17045309]
  33. Santoni-Rugiu E, Silverman JA: Functional characterization of the rat mdr1b encoded P-glycoprotein: not all inducing agents are substrates. Carcinogenesis. 1997 Nov;18(11):2255-63. [PubMed:9395229]
  34. Sieczkowski E, Lehner C, Ambros PF, Hohenegger M: Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells. Int J Cancer. 2010 May 1;126(9):2025-35. doi: 10.1002/ijc.24885. [PubMed:19739078]
  35. Chiu LY, Ko JL, Lee YJ, Yang TY, Tee YT, Sheu GT: L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. Toxicol Lett. 2010 Feb 15;192(3):408-18. doi: 10.1016/j.toxlet.2009.11.018. Epub 2009 Nov 26. [PubMed:19944135]
  36. Karlsson JE, Heddle C, Rozkov A, Rotticci-Mulder J, Tuvesson O, Hilgendorf C, Andersson TB: High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells. Drug Metab Dispos. 2010 Apr;38(4):705-14. doi: 10.1124/dmd.109.028886. Epub 2010 Jan 13. [PubMed:20071452]
  37. Jutabha P, Wempe MF, Anzai N, Otomo J, Kadota T, Endou H: Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84. doi: 10.1016/j.phrs.2009.07.002. Epub 2009 Jul 21. [PubMed:19631272]
  38. Kugawa F, Suzuki T, Miyata M, Tomono K, Tamanoi F: Construction of a model cell line for the assay of MDR1 (multi drug resistance gene-1) substrates/inhibitors using HeLa cells. Pharmazie. 2009 May;64(5):296-300. [PubMed:19530439]
  39. Dahan A, Amidon GL: Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7. doi: 10.1152/ajpgi.00102.2009. Epub 2009 Jun 18. [PubMed:19541926]
  40. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7. doi: 10.1111/j.1349-7006.2009.01213.x. Epub 2009 May 12. [PubMed:19493273]
  41. Dahan A, Sabit H, Amidon GL: The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009 Jun;11(2):205-13. doi: 10.1208/s12248-009-9092-5. Epub 2009 Mar 25. [PubMed:19319690]
  42. Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, Fromm MF: Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther. 2000 May;293(2):376-82. [PubMed:10773005]
  43. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674]
  44. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684]
  45. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019]
  46. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186]
  47. Dagenais C, Graff CL, Pollack GM: Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol. 2004 Jan 15;67(2):269-76. [PubMed:14698039]
  48. Borgnia MJ, Eytan GD, Assaraf YG: Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71. [PubMed:8621716]
  49. Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G: Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26. [PubMed:15180340]
  50. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM: Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997 Jun;51(6):913-21. [PubMed:9187257]
  2. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocyte...
Gene Name
ABCC3
Uniprot ID
O15438
Uniprot Name
Canalicular multispecific organic anion transporter 2
Molecular Weight
169341.14 Da
References
  1. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. [PubMed:11585759]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
May be an organic anion pump relevant to cellular detoxification.
Gene Name
ABCC4
Uniprot ID
O15439
Uniprot Name
Multidrug resistance-associated protein 4
Molecular Weight
149525.33 Da
References
  1. Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, Kruh GD: Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50. [PubMed:12036927]
  2. Bai J, Lai L, Yeo HC, Goh BC, Tan TM: Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int J Biochem Cell Biol. 2004 Feb;36(2):247-57. [PubMed:14643890]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
Gene Name
SLC22A5
Uniprot ID
O76082
Uniprot Name
Solute carrier family 22 member 5
Molecular Weight
62751.08 Da
References
  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100]
  2. Ohashi R, Tamai I, Nezu Ji J, Nikaido H, Hashimoto N, Oku A, Sai Y, Shimane M, Tsuji A: Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol. 2001 Feb;59(2):358-66. [PubMed:11160873]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Lespine A, Dupuy J, Orlowski S, Nagy T, Glavinas H, Krajcsi P, Alvinerie M: Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3). Chem Biol Interact. 2006 Feb 25;159(3):169-79. Epub 2005 Dec 27. [PubMed:16384552]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-71. [PubMed:10421612]
  2. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name
ABCC10
Uniprot ID
Q5T3U5
Uniprot Name
Multidrug resistance-associated protein 7
Molecular Weight
161627.375 Da
References
  1. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. [PubMed:12527806]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9. [PubMed:12134946]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without...
Gene Name
SLC22A4
Uniprot ID
Q9H015
Uniprot Name
Solute carrier family 22 member 4
Molecular Weight
62154.48 Da
References
  1. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73. [PubMed:10215651]
  2. Wu X, George RL, Huang W, Wang H, Conway SJ, Leibach FH, Ganapathy V: Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochim Biophys Acta. 2000 Jun 1;1466(1-2):315-27. [PubMed:10825452]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, Keri G, Orfi L, Nemet K, Sarkadi B: High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol. 2004 Jun;65(6):1485-95. [PubMed:15155841]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Oostendorp RL, van de Steeg E, van der Kruijssen CM, Beijnen JH, Kenworthy KE, Schinkel AH, Schellens JH: Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors. Drug Metab Dispos. 2009 Apr;37(4):917-23. doi: 10.1124/dmd.108.024901. Epub 2009 Jan 12. [PubMed:19139163]

Drug created on June 13, 2005 07:24 / Updated on July 19, 2018 17:49